

III. Remarks


Applicants have amended the specification as requested by the Examiner. The Sequence ID identifier has been added to the claims.

No new matter is added by the amendments, only a reformatting of the information that was already presented in the specification, sequence listing and claims as originally filed.

IV. Conclusion

Reconsideration of the pending claims as amended and allowance is requested. Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Respectfully submitted,



Dated: February 22, 2005

(847)383-3372

(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA